Summary.-The life span of C57/Bl mice inoculated with Lewis lung carcinoma cells was prolonged if the mice were pre -immunized with membranes from these cells infected in vitro with influenza virus. Likewise, BALB/c mice were protected against the malignant tumour WEHI-ll by prior immunization with extracts of cultured WEHI-ll cells which had been infected with influenza virus or Semliki Forest virus (SFV). Partially purified SFV grown in WEHI-ll cells also protected mice from cancer grafts but neither highly purified SFV nor the glycoprotein from the envelope of this virus protected the mice. It is concluded that SFV-induced immunopotentiation against cancer is not due to covalent linkage of tumour specific transplantation antigen (TSTA) to viral envelope protein but more probably is due to the apposition of viral glycoprotein and cellular TSTA in the plasma membrane of the cancer cell.
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THERE have been several reports that membranes from cancer cells infected with enveloped viruses protect mice or rats against tumour challenge more effectively than do membranes from uninfected cells. Viruses used include influenza strain WSA (Lindenmann and Klein, 1967a, b; Hakkinen and Halonen, 1971; Boone, Blackman and Brandchaft, 1971; Boone and Blackman, 1972; , influenza strain WSN (Klein, 1974) , influenza A2 Hongkong , strains of avian influenza virus (Lindenmann and Klein, 1967a; Lindenmann, 1970) , Newcastle disease virus (Axler and Girardi, 1970; Beverley, Lowenthal and Tyrrell, 1973; Eaton, Heller and Scala, 1973) , vesicular stomatitis virus (Lindenmann, 1970; Hakkinen and Halonen, 1971; Boone et al., 1974) and Friend leukaemia virus (Kobayashi et al., 1970) . Possible mechanisms of this virus induced immune potentiation have been discussed by Mitchison (1970) , Lindenmann (1973 Lindenmann ( , 1974 and . One of the suggested mechanisms is that the viral antigen acts as a "helper determinant " (Mitchison, 1970) . This paper reports attempts to elucidate the spatial relationship between the hypothetical " helper determinant" and the tumour specific transplantation antigen (TSTA). A feature common to many, and probably all, budding viruses is that the virus coded envelope proteins of the virion are glycosylated by cell coded sugar transferases during virus synthesis in infected cells. Hence, the carbohydrate moiety of any virus coded glycoprotein is uniquely characteristic of the cell type in which that virus grew (see Fenner et al., 1974 White, 1974) . Virions of Semliki Forest virus (SFV), a group A arbovirus (togavirus), are even simpler in their structure and also possess two envelope glycoproteins (Simons, Keranen and Kddridinen, 1973; Ivanic, 1974 Cells were cultured in vitro in flat glass bottles, or roller bottles, in DMEM containing 10% FCS, 0-030o glutamine, 0.01% streptomycin, 100 u/ml of penicillin G, 2-5 x 10-4 % Fungizone, 0-01 mol/l HEPES buffer and 0-170% sodium bicarbonate; the medium was adjusted to pH 7-3 with 1 N sodium hydroxide.
Propagation and purification of virus.-Influenza virus was propagated in the allantoic cavity of 11-day old embryonated hens' eggs. Eggs were inoculated with about 1000 " egg infectious doses " and incubated at 35°C for 40 h. The eggs were then chilled and infected allantoic fluids were harvested, clarified by low speed centrifugation, filtered through a washed 220 ,um Millipore membrane, snap-frozen and stored at -70°C for stock virus.
To prepare concentrated influenza virus for vaccine, the infected allantoic fluid was cooled, clarified by low speed centrifugation and mixed with an equal volume of ammonium sulphate solution (neutralized with 1 N NaOH) saturated at 4°C. Flocculated virus was concentrated by centrifugation for 20 min at 8,000 g in an International B20 centrifuge. Following resuspension in PBS, the concentrated virus was centrifuged into a density gradient of glycerol/6500 (xv/w) sucrose/4000 (w/v) Stored cells were thawed, disrupted with a teflon-in-glass homogenizer (20 strokes) and centrifuged for 15 min at 3000 g in an International B20 centrifuge. All operations were carried out at a temperature near to 0°C to reduce the activity of any released lysosomal enzymes. The pellet was resuspended using the homogenizer, then subjected to ultrasonic vibration with an MSE 150 watt ultrasonic disintegrator for 2 min, and centrifuged at 3000 g as above. The pooled 3000 g supernatants were clarified by centrifugation at 7000 g. The low-speed pellets were resuspended in PBS and combined to constitute the " cell debris" fractions, while the final low speed supernatant was centrifuged at 100,000 g for 45 min in an International B60 rotor. The pellet recovered from this spin vwas designated the ' cell membrane fraction.
Influenza Polyacrylarnide gel electrophoresis.-Protein or virus samples (50-100 ,tl) were mixed with 100 ,ul of sample buffer (10% v/v glycerol, 500 v/v mercaptoethanol, 3%o w/v sodium dodecyl sulphate in 0-06 mol/l tris-HCl, pH 6-8) and a trace of bromophenol blue, and heated to 90TC for 2 min. Samples were applied to 90 mm 8-75% w/w polyacrylamide gels (with an 8 mm 3%o w/w stacking gel) cast in 12-0 x 0 5 cm glass tubes using the procedure of Laemmli (1970) . Electrophoresis (2 mA/gel) was continued until the tracking dye was 10 mm from the bottom of the gel. Gels were stained for 2 h at 37°C in 0-05% Coomassie Brilliant Blue R250 in methanol: acetic acid: water (5: 1: 5) and destained with 3 changes of 7 5% v/v acetic acid in 10% v/v ethanol in water.
RESULTS
In preliminary experiments a number of budding viruses were grown in several tumour cell lines and the infected cell homogenates were tested for their ability to protect mice against subsequent challenge with the homologous tumour. Significant protection was obtained with influenza virus grown in Lewis lung carcinoma (LLC) cells and with influenza virus or SFV grown in WEHI-1 1 cells. These virus-cell combinations were chosen for further study.
Graphs of survival time against tumour cell dose for LLC and WEHI-1 1 are shown in Figs 1 and 2 ; the time at which WEHI-1 tumours were first detected is also shown in Fig. 2 (500) and delay in the time of death of mice failing to survive (Fig. 3) Brandchaft and Boone, 1974) . To test the possibility that the enhanced immunogenicity of membranes from influenza virus infected cells could 49, 59, 62, 96, 96 55, 67, 70, 84, 96 70 41, 57, 70, 79, 89 39, 39 SFV grown in WEHI-11 or Vero cells was partially purified by differential centrifugation and Sepharose 4-B gel filtration, or highly purified by rate-zonal, followed by equilibrium-gradient centrifugation, and then inactivated with sodium desoxycholate. Viral envelope glycoprotein was purified from some of this material. BALB/c mice were inoculated i.p. in groups of 5 and challenged s.c. after 11 days with 10,000 WEHI-11 cells.
be attributed to enzymic alteration (or exposure) of tumour antigens by viral neuraminidase or by enzymes released from lysosomes of cells dying as a result of viral infection, mice were immunized with neuraminidase treated uninfected LLC membranes or with membranes from non-viable LLC cells. Neither gave a greater degree of protection against challenge than untreated uninfected membranes, suggesting that the presence of viral antigen in the LLC cell membrane fraction is important for enhanced protection.
Protection against WEHI-1 I WEHI-11 cells were harvested 16-20 h after infection with either influenza virus or SFV, at which stage all cells were found by haemadsorption to contain viral haemagglutinin in their plasma membranes. The cells were centrifuged down, resuspended 1: 10 (v/v) in saline, then disrupted by sonic vibration and heated at 56°C for 1 h to inactivate residual live virus. Groups of 10 BALB/c mice were immunized i.p. with 0-2 ml of these crude membrane preparations extracted from influenza virus infected, SFV infected or uninfected cells, then challenged s.c. 7 days later with 104 viable WEHI-11 cells.
Membranes from cells infected with either virus conferred total protection on approximately half the mice; when the experiment was terminated at 117 days no tumours were detected in any of the survivors (Fig. 4) .
Since intact influenza virions are not released from infected LLC cells or WEHI-11 cells, and since purification of the haemagglutinin from the plasma membranes of these cells presented a number of problems, it was decided to seek a virus-cell combination from which large numbers of infectious virions could be purified. Moreover, it was considered desirable to use a virus which, unlike influenza virus, contains no neuraminidase. SFV fulfilled all these requirements.
Purified SFV as immunogen SFV was found to grow productively to high titre in cultured WEHI-l1 cells. Virus released into the culture medium of WEHI-l1 or Vero cells was concentrated and partially purified by differential centrifugation and gel filtration through a Sepharose 4-B column. Virus concentrates were then freed of contaminating cell debris by rate-zonal centrifugation followed by density-equilibrium centrifugation. The glycoprotein peplomers (" spikes ") were then extracted from the purified virions by treatment with the non-ionic detergent Nonidet P40 and purified by gradient centrifugation as described in Materials and Methods.
To examine the purity of these various preparations, each specimen was then dissociated with sodium dodecyl sulphate and 2-mercaptoethanol at 90°C for 2 min at pH 6-8 and the constituent polypeptides were analysed by polyacrylamide gel electrophoresis (Fig. 5) .
The stained gels revealed the presence of a large number of contaminating proteins in the partially purified SFV concentrate (a), but the highly purified virus (gels b and c, intentionally " overloaded" in an attempt to reveal any trace contaminants) contained only the 3 proteins known to be present in SFV, viz. the internal nucleoprotein and the 2 envelope glycoproteins of almost identical molecular weight (Simons et al., 1973; Ivanic, 1974) . The preparation of envelope glycoprotein (gel d) also proved to be absolutely pure.
These several preparations were tested, together with a membrane preparation from uninfected WEHI-11 cells, for their ability to protect BALB/c mice against challenge with WEHI-11 tumour grafts (Table) . Partially purified concentrates of WEHI-11-grown SFV protected 80% of the mice, but none of the other immunogens, including purified WEHI-1 1 grown SFV and the envelope glycoprotein extracted from such virus, had any demonstrable effect.
DISCUSSION
There now seems little doubt that under certain circumstances mice may be protected against cancer by prior immunization with crude preparations of virions derived from cancer cells, or with virus infected cancer cell membranes, even if the viral multiplication cycle is abortive and no virions are produced. From our results, it is clear that the arbovirus SFV may be added to the growing list of enveloped viruses capable of mediating this protection.
It should be appreciated that the degree of protection conferred by membranes from virus infected cancer cells, though greater than that induced by membranes from uninfected cancer cells, is consistently lower than that obtained with whole irradiated cancer cells (Boone and Blackman, 1972; Beverley et al., 1973) , but that most workers are reluctant to contemplate the inoculation of nucleic acid from cancer cells (irradiated or not) into man.
The mechanism by which the immune response to the TSTA is augmented remains obscure. Definitive investigations require the use of (1) syngeneic tumours, to avoid the complications associated with allografts, and (2) immunogens freed of infectious virus, to rule out the possibility that residual live virus persists in the mouse for long enough to destroy the tumour cell graft. Most of the pioneering studies were open to question on both counts (Lindenmann and Klein, 1967a, b; Lindenmann, 1970 Lindenmann, , 1973 Lindenmann, , 1974 The most attractive hypothesis, attributable to Mitchison (1970) , is that a highly immunogenic viral antigen acts as a " helper determinant " to enhance the immunological response against the relatively weak TSTA. The topological relationship of viral antigen to TSTA in the plasma membrane or in the viral envelope is unknown. Two alternatives may be considered. The first is that the TSTA is actuallv a host cell determined carbohydrate side-chain covalently linked to the virus coded protein backbone of the viral glycoprotein molecule. The second is that strong viral antigens present in the plasma membrane of the cancer cell in close apposition to the TSTA render the latter more prominent, or facilitate T-B or T-T lymphocyte collaboration, leading to an enhanced immune response against the cancer (Mitchison, 1970) .
If the first alternative is correct, then highly purified virions or viral glycoprotein produced in tumour cells should protect recipients against tumour challenge; indeed, the specific activity of the immunogen should increase with purification as irrelevant cell proteins are progressively removed during the purification procedure. If the second alternative is correct, then the opposite should apply. Our results suggest that with the SFV-WEHI-11 virus-cell system the second alternative is operative. Although previous workers have not tested rigorously purified virus, there are indications in the literature that the same may be true with other virus-cell systems. Beverley et al. (1973) reported that partially purified Newcastle disease virus grown in S37 cells was less effective than crude infected cell homogenates. Similarly, Eaton et al. (1973) had difficulty in demonstrating protection using partially purified Newcastle disease virus. Hakkinen and Halonen (1971.) found that impure influenza or vesicular stomatitis virus concentrates were less effective than crude infected cell preparations in protecting mice against Ehrlich ascites carcinoma. In contrast, Lindenmann (1973) , using exactly the same strain of influenza virus, also in Ehrlich ascites cells, claimed that highly purified virus conferred complete protection. However, the virus used by Lindenmann was not shown by polyacrylamide gel analysis to be free of host-cell membrane proteins; and host coded proteins may be present in influenza virions (Dawson, Epstein and Hummler, 1965) albeit at a low level (Holland and Kiehn, 1970) .
Thus, it is postulated that the helper effect of viral antigens in augmenting anti-tumour immunity, in some systems at least, results not from a covalent association between viral protein and tumour antigen but from the contiguity of viral glycoprotein and TSTA in the plasma membrane of the cancer cell.
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